Dysregulation of the PI3K/mTOR pathway either through amplifications, deletions or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers. Moreover, this pathway activation is a poor prognostic marker for many tumor types and confers resistance to various cancer therapies.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K) signaling pathway is crucial to many aspects of cell growth and survival via its regulation of diverse physiological processes that include cell cycle progression, differentiation, transcription, translation and apoptosis (1). The PI3K
family of lipid kinases consists of three classes based on their substrate specificity and sequence homology. In class I PI3K, four isoforms of the catalytic subunit p110 have been identified, whereby the α and β isoforms are ubiquitously expressed and the γ and δ are mainly expressed in leukocytes (2) . Dysregulation of the PI3K class I signaling pathway, either through gene amplification or as a direct result of mutations, has been closely linked to the development and progression of a wide range of cancers. Genetic alterations in proteins of this signaling pathway include p85 (regulatory subunit of PI3Kα), p110α, PDK1, PTEN and Akt (3, 4) . The dysregulated PI3K pathway induces a myriad of downstream effectors including the mammalian target of rapamycin (mTOR). mTOR is a member of the PI3K-related kinase (PIKK) family which includes PI3K, DNA-dependent protein kinase (DNA-PK), and ataxia telangiectasia mutated (ATM). Its catalytic kinase domain is highly homologous to the lipid kinase domain of PI3K. In mammals, mTOR is the catalytic subunit in two distinct complexes, mTORC1 and mTORC2. mTORC1 controls cellular growth by integrating signals from growth factor receptors and intracellular nutrient status. mTORC2 is less well understood but plays a role in the regulation of cellular survival and cell migration (5, 6) . The mTOR signaling pathway has been suggested to be involved in multiple anticancer drug resistance mechanisms towards chemotherapeutics, but also signal transduction inhibitors (small molecule tyrosine kinase inhibitors and antibodies) (4) . Rapamycin and its analogs block mTORC1 activity and have shown single agent activity in a small subsets of cancers (7) . However resistance has been shown to develop through activation of the PI3K signaling pathway including activation of mTORC2 (8) . To overcome this and also broaden applications, the rapalogues are now being evaluated in combination with other standard or targeted therapies. We have taken another approach which is to directly block mTOR kinase with compounds that bind the ATP site and therefore block both mTOR complexes. In addition, we wanted to generate compounds that also inhibit PI3K with equivalent potency to overcome one of the key resistance pathways activated by mTORC1 inhibition.
VS-5584 is a novel low molecular-weight compound with high and equivalent potency against mTOR and all PI3K class I isoforms but with no relevant activity for more than 400 lipid and protein kinases and thereby having a differentiating profile compared to currently available clinical stage compounds. The present study characterizes the pharmacodynamic and pharmacokinetic relationship of VS-5584 in human tumor models and demonstrates superior efficacy and broad anti-tumor efficacy of VS-5584 and tolerability across a range of cancer types. 
MATERIAL AND METHODS

Compounds and Reagents
VS-5584 (formerly named SB2343), as depicted in Table 1 : 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine was discovered and synthesized by S*BIO Pte Ltd (Singapore). Synthesis of VS-5584 is described in a published patent application WO WO2010114484 (9) . Gefitinib was purchased at LC Laboratories (Woburn, MA), 5-FU and everolimus were obtained from Sigma-Aldrich (Singapore). For in vivo studies, VS-5584, everolimus and gefitinib dosing solutions were prepared in 0.5% methylcellulose (w/v) and 0.1 % Tween-80 in H 2 O (MC/Tween). 5-FU was dissolved in sterile saline. IFN-α, IFN-γ, IL-2 and IL-3 were purchased from i-DNA (Singapore).
In vitro kinase assays
For details on the in vitro kinase assays for mTOR, class I PI3K α/β/χ/δ, ATM, ATR and for kinase profiling at Invitrogen, Millipore, Ambit and ProQinase please see 
Western Blot analysis
Cells were lysed and proteins immuno-precipitated as previously described. (10) . Western blots were performed according to standard methods. pAkt (S473) (Cat #9271), pAkt (T308) (Cat #2965), pS6 ribosomal protein (S240/244), pmTOR (S2481) (Cat #2974), pErk1/2 (T202/y204) (Cat# 4376), and anti-rabbit IgG, HRP-linked (Cat #7074) antibodies were purchased from Cell Signaling Technology (Beverly, MA). β-actin (Cat #A2066) from Sigma (St Louis, MO). The images were captured digitally using the LAS-3000 Life Science Imager from Fujifilm (Tokyo, Japan). Densitometric analysis was performed using the MultiGauge software (v3.1) from Fujifilm. 
In Vivo Efficacy Studies
RESULTS
Kinase selectivity spectrum of VS-5584
VS-5584, 5-(9-isopropyl-8-methyl-2-morpholin-4-yl-9H-purin-6-yl)-pyrimidin-2-ylamine was discovered a novel purine analog (11, 12) (Table 1) , was generated with the aid of computational chemistry to be a small-molecule ATP competitive inhibitor of PI3K and mTOR kinases with favourable pharmaceutical properties. The synthesis of the compound will be published in a separate manuscript (13) . To further explore its kinase selectivity spectrum, VS-5584 was profiled against two large kinase panels (>400 kinases) covering all major families of the human protein and lipid kinome. Further analysis of 320 kinases (including NEK2 and BTK) in a radiometric kinase assay platform showed that no kinase showed an IC 50 < 300 nM except for the PIKK family (data not shown).
Modulation of PI3K/mTOR signaling pathways by VS-5584
To investigate whether the enzyme inhibitory properties of VS-5584 translate into modulation of the PI3K/mTOR signaling pathway, the phosphorylation status of downstream substrates were determined in human cancer cell lines with different genetic backgrounds. and the mTOR signaling cascade after 3 h (Fig. 1A) . The IC 50 values for pS6(S240/244), pAkt(S473) and pAkt(T308) were 20, 23 and 15 nM.
Next, the effect of VS-5584 on signaling of over-expressed or mutated receptor tyrosine kinases was studied. In the FLT3-ITD harboring MV4-11 cells, VS-5584 blocked pAkt(S473) and pAkt(T308) with an IC 50 of 12 and 13 nM (Fig. 1B) . Everolimus (also known as RAD001, Fig. 1B ), an inhibitor of mTORC1 but not mTORC2, was not able to inhibit phosphorylation of Akt (Fig. 1C ). In the HER2 over-expressing gastric cancer cell line NCI-N87, VS-5584 potently blocked pS6. Interestingly, pAkt(S473) and pAkt(T308) showed a higher IC 50 compared to pS6. MAPK activity was not blocked up to 1000 nM of VS-5584, showing specificity for the PI3K signaling pathway (Fig. 1D ).
Furthermore, we investigated whether an activated Ras/MAPK pathway interferes in the inhibition of PI3K/mTOR by VS-5584. We treated Colo205 (BRAF V600E, mTOR P1193L) and MDA-MB-231 (BRAF G464V, KRAS G13D) with VS-5584 for 3 h. Despite having an activated MAPK pathway, the IC 50 of VS-5584 on pAkt and pS6 was not higher compared to PC3, MV4-11 or NCI-N87 ( Fig. 1E/F ).
In addition to the effects of VS-5584 on cell lines with known mutations in the PI3K/MAPK pathway, studies were performed on HuH7 cells, which do not have any known genetic alterations in these signaling pathways. Similar to our earlier findings, VS-5584 blocked PI3K and mTOR signaling in the same range with IC 50 of 20 nM for pS6(S240/244) and 10 nM for pAkt(S473) (Fig. 1G ).
Overall, these data demonstrate that VS-5584 effectively permeates cells to modulate signaling pathways downstream of PI3K/mTOR, independent of the genetic background of the cells.
VS-5584 potently blocks proliferation in a broad spectrum of tumor cells
As the PI3K/mTOR signaling pathway regulates important functional responses including cell proliferation, the effects of VS-5584 on a panel of 51 cancer cell lines derived from both liquid and solid tumors of human origin were investigated. Overall, VS-5584 showed high anti-proliferative activity in a broad spectrum of cancer cells, with H929 (multiple myeloma) showing the highest sensitivity in our panel (IC 50 = 48 nM) (Supplementary Fig. 2 ). Of note, VS-5584 was potent against many rapamycin-resistant cell lines.
Pharmacokinetic and Pharmacodynamic properties of VS-5584
In order to investigate the efficacy of VS-5584 in disease models, the pharmacokinetic and pharmacodynamic (PK/PD) profile of VS-5584 was determined to enable the selection of an optimal dosing schedule. A single oral dose of VS-5584 was rapidly absorbed with a t max of 0.9 h and an elimination half-life of 10 h (Supplementary Fig. 3 ). To determine the PK/PD relationship in tumors, PC3-tumor bearing mice were treated with a single dose of VS-5584 and plasma and tumors were harvested after 6 h and analyzed for concentrations of VS-5584 and effects on target efficacy biomarkers. Plasma levels of VS-5584 increased dosedependently ( Fig. 2A) . Plasma PK was not significantly different to tumor PK. Drug levels exceeded the IC 50 for inhibition of the target kinases in the enzymatic and cell based assays starting from 3.7 mg/kg. Dose-dependent inhibition of pAkt(S473) and pS6(S240/244) was observed in tumor tissue with complete inhibition from 33 mg/kg (EC 50 of 4.2 and 1.7 mg/kg, Fig. 2B ). To study the time course of drug levels and inhibition of target kinase signaling in plasma and tumor, PC3-tumor-bearing mice were treated with a single oral dose of 33mg/kg VS-5584 and the tissues harvested 1 h, 6 h, and 24 h post-dosing. The plasma concentration of VS-5584 following the 33 mg/kg dose of VS-5584 was highest 1 h after dosing (1221 ng/mL or 3.55 µM) and was still above concentrations required to block the targets in in vitro assays after 24h (15 ng/ml or 43 nM) (Fig. 2C) . pAkt(S473) and pS6(S240/244) were blocked by 90 % or more within 1 h of VS-5584 treatment and remained inhibited by 60-70 % after 24 h (Fig. 2D) .
Having established the PK/PD relationships for VS-5584 after single dosing and showing that a single dose was well tolerated up to 100 mg/kg, the maximum tolerated dose (MTD) after chronic dosing was determined. Male Balb/C nude mice were dosed once daily for 14 consecutive days. Doses of 25 mg/kg and 35 mg/kg VS-5584 were well tolerated with maximum observed body weight losses of 3.1 % and 13.9 % (data not shown).
Peripheral blood cell counts remained within normal levels without significant changes throughout dosing after the 25 and 35 mg/kg doses of VS-5584 (data not shown).
In summary, VS-5584 demonstrates good oral bioavailability with dose-linear PK and a profound and long lasting PD response in tumor tissue following a single oral dose in tumor bearing mice.
VS-5584 is efficacious in a PTEN null human prostate PC3 xenograft model
For evaluation of efficacy in a rapamycin-sensitive PC3 engraftment model, tumorbearing mice were treated with VS-5584 for 28 days in comparison to the rapalogue everolimus. VS-5584 was well tolerated at both doses tested (11 and 25 mg/kg) with minimal weight loss (mean 4.7 % on d27, Supplementary Fig. 4 ). Treatment with VS-5584 led to significant tumor growth inhibition (TGI) of 79 % and 113 % for 11 and 25 mg/kg respectively. Everolimus at 5 mg/kg showed a TGI of 133 % (Fig. 3A) .
Having demonstrated that acute dosing of VS-5584 led to significant inhibition of cellular biomarkers in tumor tissue, the PD marker modulation in the tumors was also determined after chronic dosing. VS-5584 induced a near-complete inhibition of pS6 and pAkt(S473) 6 h after the last dose on day 27 (95 % and 85 % respectively at 25 mg/kg). The lower dose of 11 mg/kg of VS-5584 also induced significant inhibition of pS6 and pAkt(S473) (79 % and 38 % respectively, Fig. 3B/C) .
These results further demonstrate the effective and long lasting inhibition of PI3K and mTOR signaling by VS-5584 in tumor tissue and that this results in significant inhibition of tumor growth at well tolerated doses. 
aggressive tumor model and showed a dose-dependent efficacy with TGIs of 45 %, 85 % and 86 % for 11, 25 or 35 mg/kg (Fig. 3D ). Everolimus at 5 mg/kg led to 29 % TGI, which was not statistically significant. VS-5584 also showed dose-dependent efficacy based on final tumor weights (Fig. 3E) . Furthermore, analysis of PD markers showed that 1h after the last dose on day 17, tumors of the 25 mg/kg group showed a significant reduction of 95 % and 85 % of pS6 and pAkt (Fig. 3F) . which only binds to functional blood vessels, was injected 30 min before harvesting the tumors. The overall vessel score of the whole tumor sections was significantly reduced in the 25 mg/kg treatment group, whereas Everolimus treatment did not reduce the vessel score significantly (Fig. 3G, Supplementary Fig. 5 ).
In summary, we have demonstrated that a well-tolerated dose of VS-5584 blocks mTOR and PI3K signaling in tumor tissue and reduces the number of functional blood vessels in the tumor and is efficacious in a rapalogue-resistant COLO-205 xenograft model.
VS-5584 is efficacious in a FLT3-ITD AML xenograft model
MV4-11 xenografts were treated for 26 consecutive days with 3.7 and 11 mg/kg of VS-5584.
VS-5584 treatment induced dose-dependent inhibition of tumor growth (28 % for 3.7 mg/kg and 76 % for 11 mg/kg, Supplementary Fig. 6A ). All doses were well tolerated with no significant body weight loss (Supplementary Fig. 6B ). To investigate target modulation, MV4-11 harboring mice were given a single dose of 3.7 and 11 mg/kg VS-5584 and tumor samples taken 4 h and the tumor lysates were analyzed for pAkt(T308). VS-5584 treatment was able to block pAkt(T308) already at the lowest dose of 3. In summary, this data demonstrates the VS-5584 is also efficacious at low and well tolerated dose in liquid tumor model, namely the FLT3-ITD harboring MV4-11 xenograft model.
VS-5584 is efficacious as a single agent and has synergistic effects in combination
with an EGFRi in a gastric xenograft model. Having demonstrated inhibition of tumor growth in this model using VS-5584 as monotherapy, it was of interest to determine whether VS-5584 could be safely and beneficially combined with an EGFRi, a targeted therapy which recently has been tested in Phase 2 in gastric cancer. Monotreatment of NCI-N87 tumor-bearing mice with VS-5584 at 11 mg/kg or gefitinib at 150 mg/kg resulted in a TGI of 88 % and 17 % (p<0.001, Fig. 4E , structure of gefitinib is shown in Fig. 4F ), which was only statistically significant for VS-5584.
VS-
Combination therapy at the same dose levels resulted in a TGI of 121 % (p<0.001). The
Clarke's combination index was -0.1 indicating synergism (14) . The combination was very well tolerated with no significant body weight loss (data not shown). Our data demonstrates that this tumor is highly sensitive to VS-5584 as a single agent and that the drug can act synergistically with gefitinib.
Drug sensitivity profiling in the Genomics of Drug Sensitivity in Cancer (GDSC) cell line panel
To identify putative biomarkers of sensitivity, a large panel of genetically characterized cancer cell lines was screened with VS-5584 to identify genomic features associated with drug sensitivity (15, 16) . The cell line collection includes many common and rare cancer sub- types, and encompasses much of the genomic diversity found in cancer and which appears to be important in influencing drug response (Supplementary Table 1 IC 50 of 147 nM as compared to 394 nM (n = 374) in cell lines with neither mutation. In contrast, a co-incident mutation in KRAS, which is frequently mutated in lung and colorectal cancers together with PIK3CA, had the opposite effect and weakly suppressed the sensitivity of PI3K-mutated cells to VS-5584 (Supplementary Fig 7A) . This slight decrease in sensitivity was not statistically significant. Moreover, we did not observe increased sensitivity of ERBB2 amplified cells with co-incident PIK3CA mutations to the EGFR/ERBB2 inhibitor, BIBW2992
( Supplementary Fig. 7B and Supplementary Table 1) . Collectively, our data indicate that although sensitivity to VS-5584 is associated with mutation of PIK3CA, the greatest sensitivity is observed in PIK3CA-mutated breast cancer cell lines with co-incident ERBB2 amplification.
Mutation of EZH2, encoding for a Histone-lysine N-methyltransferase involved in regulation of chromatin structure and gene expression, was also significantly correlated with sensitivity ( Fig. 5A and Supplementary Table 2 ). The mechanism of this sensitivity is currently unclear and warrants further investigation. Interestingly, mutations of APC, MYCL1 or MYCN were correlated with drug resistance (Fig 5A) . 
DISCUSSION
The PI3K/mTOR pathway is one of the most commonly activated signaling pathway in human cancer. Many players in the PI3K pathway are either amplified, have undergone loss of heterozygosity or are targeted by somatic or germline alterations.(4) These observations led to the development of rapamycin and rapalogues which are allosteric, irreversible inhibitors of mTORC1, for cancer treatment. Temsirolimus was approved for metastatic renal cell carcinoma in 2007, serving to validate the PI3K/mTOR pathway as a therapeutic target in cancer (17) . Despite some success in selected tumor types, rapalogues generally showed very limited anticancer efficacy as single agents and mostly lead to cytostatic effects (18) .
Negative feedback loops involving S6K have been described to have dramatic effects on drug responses for mTORC1 inhibitors (19) . Activated mTORC1 initiates a negative feedback cascade via S6K to downregulate PI3K activity. Treating tumors with rapalogues can result in increased PI3K/Akt activity leading to an enhanced proliferation rate of the tumor (19) . Some ATP-competitive mTOR TKI inhibitors that inhibit both mTORC1 and 2, such as OSI-027, AZD8055 and INK128 have been developed and are currently undergoing clinical trials. However, resistance to these selective mTORC inhibitors can still arise via the PI3K feedback mechanism, by increased Akt(T308) phosphorylation or activation of Aktindependent PI3K targets (20) . We have demonstrated herein that VS-5584, with its selective PI3K/mTOR kinase activity, can overcome these feedback signaling mechanisms.
Furthermore, up-regulation of the RAS-MAPK pathway which occurs after mTORC1 inhibition alone, was not detected with VS-5584 treatment since it simultaneously blocks mTORC2 and PI3K as well as mTORC1 (21) .
Interestingly, the activity of VS-5584 on inhibition of target modulation biomarkers was independent of the genetic background of the cancer cells indicating that PTEN loss or mutation status of upstream receptor tyrosine kinases do not necessarily predict inhibition of these events. 
In order to identify genomic alterations which affect tumor cell response towards pathway inhibition by VS-5584 treatment, we screened across a large numbers of cancer cell lines to identify genetic biomarkers of sensitivity. Using this unbiased approach we identified that mutations of EZH2 or PIK3CA are correlated with drug sensitivity, whereas mutations of APC, MYCL1 or MYCN are correlated with drug resistance. Notably, the greatest sensitivity to VS-5584 was associated with breast cancer cells bearing co-incident amplification of ERBB2 in addition to a PIK3CA mutation. The precise reasons for this sensitivity are currently unclear but may reflect an enhanced requirement for signaling through the PI3K/mTOR pathway in this specific genetic context. Indeed, mutations in PIK3CA in breast cancer are indicators of sensitivity to the antitumor effects of the PI3K inhibitor GDC-0941 (22). Collectively, these results indicate that co-incident mutation of PIK3CA and amplification of ERBB2 may have potential utility as biomarkers of sensitivity to VS-5584 and may prove useful for patient stratification during clinical testing.
In contrast, since mutations in APC, MYCL1 or MYCN were associated with drug resistance these may provide genetic markers for patient exclusion. Moreover, these data provide a rationale to explore combinations of VS-5584 with therapies that target pathways activated by these mutations.
The PI3K pathway has been shown to play an important role in tumor angiogenesis by regulating the production of vascular endothelial cell growth factor (VEGF) (23, 24) . We showed that treatment of highly vascularized COLO-205 xenografts with VS-5584 reduced the average number of functional blood vessels within the tumor. The therapeutic effect of VS-5584 may therefore be due to direct effects on tumor cells as well as an effect on tumor vascularisation, as reported for other compounds blocking either PI3K or mTOR (25) . 
